Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer

This is a randomized clinical trial comparing the outcomes of short-course chemoradiation consisting in stereotactic boost to the gross tumor and de-esclalated chemoradiation to the elective neck in human papilloma associated oropharynx cancer vs. the current standard 7-week course chemoradiation.

Trial Details

NCT ID
NCT04178174
Phase
PHASE3
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • SABR boost and de-escalated chemoradiation
  • Standard chemoradiation
Locations (sample)
  • London, Ontario, Canada|42.98339,-81.23304
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Age ≥18 years
  • Ability to provide written informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  • Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →